Skip to main content

CORRECTION article

Front. Pharmacol., 12 August 2024
Sec. Respiratory Pharmacology

Corrigendum: Extracellular HSP90α interacts with ER stress to promote fibroblasts activation through PI3K/AKT pathway in pulmonary fibrosis

Jinming Zhang&#x;Jinming Zhang1Wenshan Zhong&#x;Wenshan Zhong1Yuanyuan Liu&#x;Yuanyuan Liu1Weimou ChenWeimou Chen1Ye LuYe Lu1Zhaojin ZengZhaojin Zeng1Yujie QiaoYujie Qiao1Haohua HuangHaohua Huang1Xuan WanXuan Wan1Wei LiWei Li2Xiaojing MengXiaojing Meng3Fei ZouFei Zou3Shaoxi Cai
Shaoxi Cai1*Hangming Dong
Hangming Dong1*
  • 1Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China
  • 2Department of Dermatology and The Norris Comprehensive Cancer Centre, University of Southern California Keck Medical Centre, Los Angeles, CA, United States
  • 3School of Public Health, Southern Medical University, Guangzhou, China

A Corrigendum on
Extracellular HSP90α interacts with ER stress to promote fibroblasts activation through PI3K/AKT pathway in pulmonary fibrosis

by Zhang J, Zhong W, Liu Y, Chen W, Lu Y, Zeng Z, Qiao Y, Huang H, Wan X, Li W, Meng X, Zou F, Cai S and Dong H (2021). Front. Pharmacol. 12:708462. doi: 10.3389/fphar.2021.708462

In the published article, there were two errors in Figure 3B, D as published. The Masson staining picture in the TUDCA group was misplaced in Figure 3B. Additionally, the Western blot picture of GRP78 was misplaced in Figure 3D. After checking the raw data, the misplaced Masson staining picture of TUDCA group in Figure 3B and the Western blot picture of GRP78 in Figure 3D were corrected. The corrected Figure 3 and its caption appears below.

Figure 3
www.frontiersin.org

Figure 3. ER stress in the lung fibroblasts is critical for pulmonary fibrosis progression. (A) Experimental scheme of the mouse model of bleomycin-induced pulmonary fibrosis. Mice were intratracheally injected with saline or bleomycin (3 mg/kg) at day 0. On day 1, mice were administrated with TUDCA (50 mg/kg) or DMSO by intraperitoneal injection every 2 days. Mice were sacrificed on day 21 (n = 10 for each group). (B) Histological images and collagen deposition of the lung tissue was detected by H&E and Masson staining. Scale bar = 100 μm. (C) Representative images showing GRP78 and α-SMA staining of lung tissues of mice treated with saline, bleomycin without or with TUDCA. Scale bar = 100 μm. (D, E) Western blot analysis of expression of GRP78 and α -SMA. (F, G), IMR90 were pre-treated with TUDCA (100 μM) for 2 h and followed by TGF-β1 (10 ng/mL) for 24 h. The expression levels of GRP78 and α-SMA was measured by Western blot. β-actin was used as an internal control. *p < 0.05, **p < 0.01.

In the published article, there was an error in Figure 7B. The IHC staining picture was misplaced in Figure 7B. After checking the raw data, the misplaced IHC staining picture in Figure 7B was corrected. The corrected Figure 7 and its caption appears below.

Figure 7
www.frontiersin.org

Figure 7. Monoclonal antibody 1G6-D7 inhibits ER stress in the bleomycin-induced pulmonary fibrosis model. (A) Schematic diagram of mouse model establishment (n = 10 for each group). (B) Representative images showing GRP78 and α-SMA staining of lung tissues of mice in the prophylactical model. Scale bar = 100 μm. (C) Representative images showing GRP78 and α-SMA staining of lung tissues of mice in the therapeutical model. Scale bar = 100 μm. Western blot analysis of the expression of GRP78 and α-SMA in the prophylactical model (D, E) and therapeutical model (F, G). β-actin was used as an internal control. *p < 0.05, **p < 0.01.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: extracellular Hsp90α, er stress, fibroblasts activation, PI3K/AKT, pulmonary fibrosis

Citation: Zhang J, Zhong W, Liu Y, Chen W, Lu Y, Zeng Z, Qiao Y, Huang H, Wan X, Li W, Meng X, Zou F, Cai S and Dong H (2024) Corrigendum: Extracellular HSP90α interacts with ER stress to promote fibroblasts activation through PI3K/AKT pathway in pulmonary fibrosis. Front. Pharmacol. 15:1296214. doi: 10.3389/fphar.2024.1296214

Received: 18 September 2023; Accepted: 31 July 2024;
Published: 12 August 2024.

Edited and reviewed by:

Paolo Montuschi, Catholic University of the Sacred Heart, Italy

Copyright © 2024 Zhang, Zhong, Liu, Chen, Lu, Zeng, Qiao, Huang, Wan, Li, Meng, Zou, Cai and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Hangming Dong, dhm@smu.edu.cn; Shaoxi Cai, hxkc@smu.edu.cn

These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.